Justis Ehlers, MD
Ophthalmology · Cleveland, OHNPI 1235346248
Payments from drug & device makers
Across 283 payments — averaging $17,791 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2.4M
- AstraZeneca$1.1M
- AbbVie$456K
- F. Hoffmann-la Roche AG$277K
- Alcon Research LLC$267K
- Boehringer Ingelheim International GmbH$132K
- plus $405K from 17 others
Across 40 payments — averaging $1420.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$32K
- Astellas Pharma Global Development$15K
- Novartis Pharma AG$4K
- F. Hoffmann-la Roche AG$4K
- Regeneron$1K
What the payments were for
- Consulting fees$602,35094%
- Speaking & faculty fees$17,2983%
- Travel & lodging$15,0312%
- Food & beverage$4,6861%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 48 | $2,365,949 |
| AstraZeneca | 3 | $1,132,350 |
| AbbVie(2 entities) | 62 | $455,672 |
| F. Hoffmann-la Roche AG | 13 | $277,421 |
| Alcon Research LLC | 17 | $266,833 |
| Boehringer Ingelheim International GmbH | 50 | $131,698 |
| Novartis Pharma AG | 3 | $111,725 |
| Novartis | 18 | $90,522 |
| Carl Zeiss Meditec, Inc. | 9 | $61,313 |
| Alcon | 29 | $51,342 |
| Boehringer Ingelheim | 5 | $35,658 |
| Astellas Pharma Global Development | 4 | $16,111 |
| Astellas Pharma US Inc | 1 | $15,000 |
| Apellis Pharmaceuticals, Inc. | 6 | $11,386 |
| Janssen Research & Development, LLC | 2 | $3,870 |
| Beaver-visitec International, Inc. | 3 | $3,400 |
| Thrombogenics, Inc. | 1 | $1,500 |
| Eyepoint US, Inc. | 1 | $1,388 |
| Astellas Pharma Inc | 1 | $739 |
| Boehringer Ingelheim Finland Ky | 2 | $465 |
| Regeneron Healthcare Solutions, Inc. | 3 | $375 |
| Ocular Therapeutix, Inc. | 1 | $34 |
| Genentech, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$198,940
- EYLEA$53,617
- Constellation$51,412
- Izervay$31,023
- Unity$16,437
- OZURDEX$13,729
- NGENUITY$10,443
- ARTEVO 800$5,940
- VEOPOZ$5,640
- RESCAN 700$2,600
- Luxor$2,100
- Syfovre$1,629
- Jetrea$1,500
- EYP-1901$1,388
- CLARUS$1,300
- FORUM$1,300
- FINESSE SHARKSKIN$643
- EYLEA HD$410
- AcrySof IQ PanOptix$106
How this compares
$5,034,761 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alphagan PBrimonidine Tartrate | 11 | $4,359 |
| Prednisolone Acetate | 122 | $3,537 |
| Difluprednate | 16 | $1,894 |
| Ketorolac Tromethamine | 42 | $862 |
| Ofloxacin | 62 | $576 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $220 |
| Cyclopentolate Hcl | 18 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P | $455,672 | $4,35911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cleveland
- Sunil SrivastavaCleveland$2.8M
- Jonathan LassCleveland$1.9M
- William WileyCleveland$1.9M
- Peter KaiserCleveland$1.5M
- Yasha ModiCleveland$883K
- Douglas RheeCleveland$461K
- Faruk OrgeCleveland$419K
- William DuppsCleveland$220K
- Marc AbramsCleveland$189K
- Shree KurupCleveland$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.